News
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results